GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

Phase 1

Completed

Conditions: Uncomplicated Urinary Tract Infections
Urinary Tract Infections

Interventions: Drug: GSK3882347
Drug: Nitrofurantoin
Drug: Placebo

First Posted Date: 2021-12-01

Last Posted Date: 2025-01-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 140

Registration Number: NCT05138822

Locations: 🇺🇸
GSK Investigational Site, Missouri City, Texas, United States

Study of GSK3511294 in Healthy Chinese Participants

Phase 1

Completed

Conditions: Asthma

Interventions: Biological: GSK3511294

First Posted Date: 2021-12-01

Last Posted Date: 2025-01-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT05140200

Locations: 🇨🇳
GSK Investigational Site, Hangzhou, China

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

Phase 1

Completed

Conditions: Pruritus

Interventions: Drug: Obeticholic acid
Drug: Linerixibat

First Posted Date: 2021-11-24

Last Posted Date: 2022-11-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 52

Registration Number: NCT05133830

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants

Phase 1

Completed

Conditions: Multiple Sclerosis
Colitis, Ulcerative

Interventions: Drug: GSK3888130B
Drug: Placebo

First Posted Date: 2021-11-23

Last Posted Date: 2025-03-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 54

Registration Number: NCT05131971

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

Phase 2

Terminated

Conditions: COVID-19

Interventions: Biological: Sotrovimab

First Posted Date: 2021-11-17

Last Posted Date: 2024-01-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 8

Registration Number: NCT05124210

Locations: 🇺🇸
GSK Investigational Site, Mesa, Arizona, United States

Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials

Phase 2

Terminated

Conditions: Neoplasms

Interventions: Other: Screening Platform

First Posted Date: 2021-10-29

Last Posted Date: 2024-02-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT05100316

Locations: 🇺🇸
GSK Investigational Site, Springfield, Missouri, United States

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Cytomegalovirus Infections

Interventions: Biological: Pentamer (low)/gB(low)/Adjuvant vaccine
Combination Product: Placebo (saline)
Biological: Pentamer (med)/gB(low)/Adjuvant vaccine
Biological: Pentamer (med)/gB(med)/Adjuvant vaccine
Biological: Pentamer (high)/gB(med)/Adjuvant vaccine

First Posted Date: 2021-10-22

Last Posted Date: 2025-05-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 339

Registration Number: NCT05089630

Locations: 🇺🇸
GSK Investigational Site, Puyallup, Washington, United States

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Phase 2

Active, not recruiting

Conditions: Meningitis, Meningococcal

Interventions: Combination Product: MenABCWY vaccine
Combination Product: Placebo

First Posted Date: 2021-10-21

Last Posted Date: 2023-01-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 300

Registration Number: NCT05087056

Locations: 🇩🇪
GSK Investigational Site, Schweigen-Rechtenbach, Germany

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Phase 2

Completed

Conditions: Chickenpox

Interventions: Biological: Investigational varicella vaccine low potency
Biological: Investigational varicella vaccine medium potency
Biological: Investigational varicella vaccine high potency
Biological: Licensed varicella vaccine Lot 1
Biological: Marketed varicella vaccine Lot 1
Biological: Measles, mumps, and rubella vaccine
Biological: Licensed varicella vaccine Lot 2
Biological: Marketed varicella vaccine Lot 2
Biological: Hepatitis A vaccine
Biological: 13-valent pneumococcal conjugate vaccine

First Posted Date: 2021-10-19

Last Posted Date: 2025-02-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 800

Registration Number: NCT05084508

Locations: 🇬🇧
GSK Investigational Site, Ohio, United Kingdom

A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Phase 2

Completed

Conditions: Infections, Meningococcal

Interventions: Combination Product: MenABCWY-2Gen low dose vaccine
Combination Product: MenABCWY-2Gen high dose vaccine
Combination Product: MenB vaccine
Combination Product: MenABCWY-1Gen vaccine
Combination Product: MenACWY-TT vaccine

First Posted Date: 2021-10-18

Last Posted Date: 2025-05-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 724

Registration Number: NCT05082285

Locations: 🇬🇧
GSK Investigational Site, Oxford, United Kingdom

Home Terms & Conditions Privacy Policy